News | October 21, 2022
Lupin launches Paliperidone Extended-Release Tablets in US
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of US $112 million in the US
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The acquisition of these two brands expands Lupin's portfolio of inhalation products in the U.S.
Revenue from operations up 26% to Rs. 768 crores
In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs
Both the partners will work towards bringing Aster Pharmacy’s in-house quality care products to serve the healthcare needs of the local population in KSA
Cupid Limited has received a purchase order from United Nations Population Fund
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
UNICEF award is worth US $98.755 million for supply of around 99.70 million doses during calendar years 2023-2027
Subscribe To Our Newsletter & Stay Updated
